Evan S. Dellon, MD: Dupilumab for EoE at ACG 2021

October 30, 2021
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

ACG represents the first major in-person conference since the COVID-19 pandemic.

Dupilumab (Dupixent) is a versatile drug that already has indications for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP).

Eosinophilic esophagitis (EoE) might soon be added into the mix for the Regeneron medication.

In an interview with HCPLive®, Evan S. Dellon, MD, MPH, Director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, said the dupilumab data is promising for patients with EoE as there is not currently a US Food and Drug Administration (FDA) treatment approved for.

“Bottom line is for the people who were treated for the first 6 months with dupilumab, for the second 6 months they sustained their response,” Dellon said. “For the people who were treated with placebo for the first 6 months and then dupilumab, their results looked good, they had a similar affect.”

Dellon presented new EoE data during the recent 2021 American College of Gastroenterology (ACG) Annual Meeting on a new daily diary for EoE patients.

Dellon also talked about the success of the first major gastroenterology in-person in almost 2 years due to the COVID-19 pandemic.

He said while everyone still wore masks out of an abundance of cation, it was still valuable seeing friends and colleagues and talking about different research endeavors.


x